๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 21 Shanghai 15 Hangzhou 8 Fuzhou 6 Chongqing 5
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing21 Shanghai15 Hangzhou8 Fuzhou6 Chongqing5
All 27 locations
Target enrolment
to

Trials with a site in Hangzhou

8 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
NCT07722494Colorectal Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
550
Wuhan, Hangzhou
2026-07-31
Not yet open
A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis
NCT07549984Atopic Dermatitis
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
16
Hangzhou
2026-04-30
Recruiting
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
NCT07483554CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
389
Hangzhou
2026-04-20
Recruiting
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
NCT07255209Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
180
Hangzhou
2025-12-29
Recruiting
Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
NCT07008287Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Observational
100
Hangzhou
2025-06-04
Recruiting
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
NCT06349408Locally Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
250
Beijing, Shanghai, Hangzhou
2025-01-10
Recruiting
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
NCT06613009Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
190
Hefei, Fuzhou, Zhengzhou, Changsha, Nanchang, Jinan, Hangzhou
2024-12-30
Active, closed
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
NCT05460767Solid Tumors or Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
504
Hangzhou
2022-08-31
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 8 of those studies with a site in Hangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Hangzhou?

6 of the 8 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hangzhou), 8 studies
PhaseStudiesRecruitingShare
Phase 14250%
Phase 32225%
Observational1112.5%
Phase 21112.5%

Most active sponsors

Lead sponsors with the most studies (Hangzhou)
Lead sponsorStudiesRecruiting
Innovent Biologics (Suzhou) Co. Ltd.86
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.